All News
Guselkumab in Psoriatic Arthritis
D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
Read Article
An ongoing axSpA cohort in Netherlands study assessed the rate of progression of nr-axSpA to AS patients over a 6 y period
Every 2 y approximately 10% of patients progressed from nr-axSpA to AS
Abst # 0907 #ACR21 @RheumNow https://t.co/gGhhssLS5N
swethaann23 swethaann23 ( View Tweet)
#ACR21 Abst#0836. TCZ switch from IV▶️SC in RA
⭐️11/37 ineffective on SC (30%)
⭐️TCZ IV >8mg/kg, no MTX, h/o ABA failure ass w/ risk of flare on SQ switch
🔥Very relevant w shortages, want more data re: confounders (adherence, disease control)
https://t.co/E9pD4SrXqz @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Getting closer to personalised medicine in AS, ECM-mediated biomarkers may help predict response to Adalimumab in AS. The biomarkers C1M, C6M and
PRO-C4 were lower in responders to adalimumab treatment after 24 weeks @RheumNow #ACR21 Abst#0915 https://t.co/K2YxPvUAwu https://t.co/w9kcBSFeG9
Dr. Antoni Chan synovialjoints ( View Tweet)
Interesting study. 79 nr-axSpA pts observed for 6 years. Every 2 yrs approximately 10% of pts progressed from nr-axSpA to AS! Next step: evaluate dz characteristics and determine potential at risk pts. Abs 0907 #ACR21 #RheumNow @RheumNow https://t.co/aRjXWjkVKg https://t.co/BiHFgDR8Kv
Dr. Rachel Tate uptoTate ( View Tweet)
Abst0898 #ACR21 @RheumNow MRI findings of Vertebral Corner Inflammation & Vertebral Corner Fat Deposition associated w/syndesmophyte formation 2 y later, ORs 1.87-2.58 for various VCI/VCFD patterns. Protection against syndesmophyte seen if both VCI and VCFD were absent (OR 0.35) https://t.co/t01nxdEwON
Olga Petryna DrPetryna ( View Tweet)
Younger patients and African Americans have a high no show rate. Need to focus on high-risk individuals and improve access to new patient appointments. @rheumnow #ACR21 abst#0610 https://t.co/3XZmXWfili
Bella Mehta bella_mehta ( View Tweet)
Monozygotic twin study in PsO patients showed a gut and skin microbiome difference compared to their "normal" twin
⭐️Ruminococcus decreased/absent in gut flora of PsO
⭐️microbiome differences even in healthy PsO skin
Abs#944
#ACR21
@RheumNow
#ACRBest
https://t.co/VlfVh5Kt3Y https://t.co/W0eSqi77lx
Robert B Chao, MD doctorRBC ( View Tweet)
This slide 👇 from Dr. Mary Crow's lecture shows how 2 categories of autoantibodies with their distinct functions can allow for different therapeutic targets in #lupus
@RheumNow #ACR21 #rheumatology https://t.co/wkthvj21cE
sheila RHEUMarampa ( View Tweet)
There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR21 Hench Lecture. Wonderful talks by Peggy Crow on #lupus pathogenesis. Tour de force since LE cells discovery. Potential sources of self-nucleic acids:
💠Endogeneous retroelements LINE-1
💠Mitochondria
💠Cell-derived nuclear debris (NETs, apoptotic)
@RheumNow https://t.co/TSdyqblYaA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Do you have trouble with no shows? Study out of Allegheny Health showed younger and black patients were among characteristics of pts at risk for new pt exam no shows. How can we do better for these pts? Thoughts? Abs 0610 #ACR21 #RheumNow @RheumNow https://t.co/MUcQarwvm6 https://t.co/Mue6By5mOV
Dr. Rachel Tate uptoTate ( View Tweet)
In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/symptom improvement compared to those w/ late dz. IV GLM better overall regardless of dz duration. Abs 0912 #ACR21 #RheumNow @RheumNow https://t.co/S2L97c7oQO https://t.co/XXpveRwwmQ
Dr. Rachel Tate uptoTate ( View Tweet)
Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy
Bella Mehta bella_mehta ( View Tweet)
Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr
Olga Petryna DrPetryna ( View Tweet)
"The strongest single predictor of both telemedicine and electronic patient portal use was English language preference." Improving access needs to include barrier awareness of SES and communication issues. Abs 0615 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/ug4xdWbnST https://t.co/t9DsAVm8aQ
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA
⭐️IL6 pts older, longer h/o RA, higher CDAI, more prior Rx
▶️ No difference in outcomes bw IL6 and TNFi (monotherapy or combo w MTX).
▶️1/3 of pts achieved LDA
Limits: real-world, unblinded
https://t.co/AJtzeMuj1T @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF
Bella Mehta bella_mehta ( View Tweet)
Novel treatment options for Giant Cell Arteritis
At this #ACR21, encouraging data will be presented on two such potential options for GCA.
https://t.co/gyVXHDRXrj
@RichardPAConway https://t.co/V2Fg8kCjWy
Links:
Dr. John Cush RheumNow ( View Tweet)